首页> 外国专利> THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF

THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF

机译:用血管紧张素受体激动剂和/或其前体治疗的治疗指导和/或治疗监测

摘要

Subject matter of the present invention is an angiotensin-receptor-agonist and/ or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, bum injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and/or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.
机译:本发明的主题是用于治疗受试者疾病的血管紧张素受体激动剂和/或其前体,•其中所述疾病选自心力衰竭,慢性心力衰竭,急性心脏衰竭(AHF),心肌梗塞(MI),中风,肝衰竭,烧伤,创伤性损伤,严重感染(微生物,病毒(例如AIDS),寄生虫病(例如疟疾)),SIRS或败血症,癌症,急性肾损伤(AKI),中枢神经系统疾病(例如癫痫发作,神经退行性疾病),自身免疫性疾病,血管疾病,低血压和休克,以及•其中所述受试者的体液样本中DPP3蛋白和/或DPP3活性的量超过预定阈值。

著录项

  • 公开/公告号WO2020128039A2

    专利类型

  • 公开/公告日2020-06-25

    原文格式PDF

  • 申请/专利权人 4TEEN4 PHARMACEUTICALS GMBH;

    申请/专利号WO2019EP86791

  • 发明设计人 BERGMANN ANDREAS;

    申请日2019-12-20

  • 分类号A61K45/06;A61K38/08;A61P31;A61P9/10;

  • 国家 WO

  • 入库时间 2022-08-21 11:10:33

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号